BCR-ABL tyrosine kinase Inhibitors
1 drugsAbout BCR-ABL tyrosine kinase
BCR-ABL tyrosine kinase is an enzyme that regulates cell growth and division. The abnormal BCR-ABL protein, created by the Philadelphia chromosome translocation, drives uncontrolled proliferation in cancer cells.
BCR-ABL is a clinically validated oncology target, though no genetic evidence directly links variations in the *BCR-ABL* gene to disease susceptibility in our dataset. The presence of the BCR-ABL fusion protein is a well-established driver of specific cancers.
BCR-ABL is targeted by one FDA-approved small molecule drug, IMKELDI, developed by SHORLA ONCOLOGY. IMKELDI is approved for 7 indications in oncology since 2024.
Top BCR-ABL tyrosine kinase Drugs
SHORLA ONCOLOGY is the only company with an approved drug targeting BCR-ABL.
The lack of competition suggests high barriers to entry or an untapped market opportunity.
BCR-ABL tyrosine kinase Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets BCR-ABL tyrosine kinase, using small molecule modality.
Exploring alternative modalities like antibodies or cell therapies could provide a competitive advantage.
BCR-ABL tyrosine kinase Clinical Trials 144 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on BCR-ABL tyrosine kinase. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 33 | 18 | 8 | 7 | 69% |
| Phase 2 | 66 | 32 | 15 | 19 | 68% |
| Phase 3 | 38 | 15 | 11 | 12 | 58% |
| Phase 4 | 7 | 3 | 1 | 3 | 75% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
BCR-ABL tyrosine kinase Drug Approval Timeline (2024 - 2024)
The first and only drug, IMKELDI, was approved in 2024.
Recent approval suggests potential for further market penetration and development of follow-on therapies.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 104 (19 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on BCR-ABL tyrosine kinase. A trial counts if an approved drug acting on BCR-ABL tyrosine kinase is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.